CoChat

MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortes, Javier, Diéras, Véronique, Patt, Debra A., Wildiers, Hans, Frenzel, Martin, Koustenis, Andrew, Baselga, Jose · 2016 · Journal of Clinical Oncology
Cited by 65

The DOI matches its Crossref record.

Abstract

510 Background: Abemaciclib is an oral, selective inhibitor of CDK4 and CDK6 dosed on a continuous schedule. In a phase 1 trial, abemaciclib demonstrated single-agent activity in refractory HR+ metastatic breast cancer (MBC) with some tumor responses occurring after 8 or more mos of therapy. Methods: MONARCH 1 is a phase 2 single-arm study designed to evaluate safety and efficacy of abemaciclib monotherapy in women with HR+/HER2- MBC whose disease progressed on or after endocrine therapy and chemotherapy. Eligible pts had measurable disease, ECOG PS of 0/1, no CNS metastases, and received at least 1 but no more than 2 lines of chemotherapy in the metastatic setting. Abemaciclib (200 mg) is administered orally on a continuous schedule every 12 hours until disease progression. A sample size of approximately 128 pts was planned to evaluate the primary objective of investigator-assessed objective response rate (ORR) using RECIST v1.1, with interim and final analyses at 8 and 12 mos after the last pt started treatment, respectively. Results: A total of 132 pts have been treated with abemaciclib monotherapy. Pts had a median of 3 lines of prior therapy for advanced disease, including a median of 2 lines of chemotherapy for advanced disease. Median age was 58 (36-89), 44.7% of pts had PS 1, 90.2% had visceral disease, and 85.6% had ≥ 2 metastatic sites. At the 8 mo interim, 35.6% of pts had received ≥ 8 cycles of therapy; the confirmed ORR (per RECIST v1.1) was 17.4%, the clinical benefit rate (CR + PR + SD ≥ 6 mos) was 42.4%, and median PFS was 5.7 mos. Of the 22 pts who remained on treatment at the 8 mo interim, 13 had responded and 9 had SD. The 5 most common TEAEs were diarrhea, fatigue, nausea, decreased appetite, abdominal pain; discontinuations due to AEs were infrequent (6.8%). Conclusions: Abemaciclib induces objective tumor responses as a monotherapy in pts with refractory HR+ HER2- MBC following multiple prior therapies. Treatment was well tolerated, allowing prolonged exposure to therapy. Updated efficacy and tolerability data will be provided at the time of presentation. Clinical trial information: NCT02102490.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.510

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 65

Metadata

Authors
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortes, J., Diéras, V., Patt, D. A., Wildiers, H., Frenzel, M., Koustenis, A., & Baselga, J.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
510-510
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2665075838
Cited by
65
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.510
The paper
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortes, J., Diéras, V., Patt, D. A., Wildiers, H., Frenzel, M., Koustenis, A., & Baselga, J. (2016). MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.510

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.